Article

New Subcutaneous Trastuzumab Option for Breast Cancer Tops SPT Week in Review

Author(s):

Top news of the week from Specialty Pharmacy Times.

5. US Can Reduce HIV Infections by 67% by 2030, Study Finds

In order for a substantial decrease of HIV infections in the United States, there needs to be a rapid expansion of prevention and treatment for individuals at risk. Read more.

4. Study: E-Cigarette Use May Lead to Same Cancer-Related Molecular Changes as Cigarettes

A recent study identified genetic changes in e-cigarette users similar to those seen in cigarette smokers. Read more.

3. Is Immunotherapy More Effective than Chemotherapy for Skin Cancer?

Study adds to the ongoing research on immunotherapy and its potential as a viable treatment for patients with cancer. Read more.

2. FDA: Elevated Risk of Blood Clots in Lungs, Death in RA Patients on Higher Dose Tofacitinib

A 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR, Pfizer) used in patients with rheumatoid arthritis increased the risk of blood clots in the lungs and death in a safety clinical trial. Read more.

1. FDA OKs Subcutaneous Herceptin Combo Therapy for Certain Breast Cancer Patients

Trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) is indicated for subcutaneous administration in certain patients with HER2-positive early and metastatic breast cancer. Read more.

Related Videos
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
Image Credit: © Krakenimages.com - stock.adobe.com
Image Credit: © Cavan - stock.adobe.com
Child with cancer -- Image credit: Alexis Scholtz/peopleimages.com | stock.adobe.com
Image Credit: © Rawpixel.com - stock.adobe.com
Image Credit: © RandyJay - stock.adobe.com
WCLC, lung cancer, NSCLC
MARIPOSA Study: Long-Term Outcomes and Next Steps for Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC